CSIMarket
 
Kamada Ltd   (NASDAQ: KMDA)
 

Kamada Ltd's Customers Performance

KMDA



 
KMDA's Source of Revenues During the corresponding time, Kamada Ltd recorded a revenue increase by 14.54 % year on year, sequentially revenue fell by -4.96 %. While revenue at the Kamada Ltd 's corporate clients

List of KMDA Customers




for the same period Kamada Ltd recorded revenue increase by 14.54 % year on year, sequentially revenue fell by -4.96 %.

List of KMDA Customers

Kamada Ltd's Business Units
Customer A    29.73 % of total Revenue
U S A    55.22 % of total Revenue
Israel    16.38 % of total Revenue
Latin America    13.42 % of total Revenue
Canada    5.99 % of total Revenue
Europe    5.24 % of total Revenue
Asia    3.72 % of total Revenue
Others    0.03 % of total Revenue
Proprietary Products    86.56 % of total Revenue
Distribution    13.44 % of total Revenue
segments    100 % of total Revenue






Kamada Ltd's Comment on Sales, Marketing and Customers



The company distributes proprietary products and has experienced disputes with distributors, including the termination of a distribution agreement with a third-party distributor in Russia and Ukraine. Its proprietary products segment operates in a highly competitive plasma industry market, competing with established biopharmaceutical companies such as CSL Behring, Takeda, Grifols S.A., Octapharma, Kedrion (excluding KEDRAB), Biotest AG, and ADMA Biologics Inc. The company competes with these firms for licenses, expertise, third-party strategic partners, and market share, particularly in the United States and European Union. Customers and markets referenced in filings include ADMA Biologics Inc., Biotest AG, CSL Behring, Grifols S.A., Kedrion, Octapharma, Takeda, and Talecris Biotherapeutics, Inc.





Kamada Ltd’s Comment on Sales, Marketing and Customers


The company distributes proprietary products and has experienced disputes with distributors, including the termination of a distribution agreement with a third-party distributor in Russia and Ukraine. Its proprietary products segment operates in a highly competitive plasma industry market, competing with established biopharmaceutical companies such as CSL Behring, Takeda, Grifols S.A., Octapharma, Kedrion (excluding KEDRAB), Biotest AG, and ADMA Biologics Inc. The company competes with these firms for licenses, expertise, third-party strategic partners, and market share, particularly in the United States and European Union. Customers and markets referenced in filings include ADMA Biologics Inc., Biotest AG, CSL Behring, Grifols S.A., Kedrion, Octapharma, Takeda, and Talecris Biotherapeutics, Inc.








KMDA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Kamada Ltd 484.56 180.46 20.20 393
SUBTOTAL 0.00 0.00 0.00 -

Sources: Kamada Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kamada Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Kamada Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.